{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:26:41Z","timestamp":1776911201467,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.amepre.2023.11.011","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:54:36Z","timestamp":1700236476000},"page":"635-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019\u20132022"],"prefix":"10.1016","volume":"66","author":[{"given":"Shilpa","family":"Rajagopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1766","authenticated-orcid":false,"given":"Jordan","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-7281","authenticated-orcid":false,"given":"Mukaila A.","family":"Raji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-0927","authenticated-orcid":false,"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2023.11.011_bib0001","unstructured":"Becerra X, PHE. Declaration: opioid renewal. Administration for Strategic Preparedness & Response (ASPR). https:\/\/aspr.hhs.gov\/legal\/PHE\/Pages\/Opioid-22Dec2022.aspx. Published 2022. Accessed February 6, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0002","unstructured":"CDC National Center for Health Statistics. U.S. overdose deaths in 2021 increased half as much as in 2020 \u2013 but are still up 15%. Centers for Disease Control and Prevention.https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm. Published 2022. Accessed August 7, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0003","unstructured":"CDC National Center for Injury Prevention and Control. DOSE dashboard: nonfatal overdose data. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/drugoverdose\/nonfatal\/dashboard\/index.html. Updated August 24, 2023. Accessed November 30, 2023."},{"issue":"2","key":"10.1016\/j.amepre.2023.11.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.amepre.2023.11.011_bib0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amepre.2023.11.011_bib0006","article-title":"Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system","volume":"2020","author":"Madras","year":"2020","journal-title":"NAM Perspect"},{"key":"10.1016\/j.amepre.2023.11.011_bib0007","unstructured":"University of Michigan Behavioral Health Workforce Research Center, the National Council for Behavioral Health. Factors that influence access to medication-assisted treatment. UMSPH.https:\/\/behavioralhealthworkforce.org\/wp-content\/uploads\/2019\/10\/Factors-that-Influence-MAT_Full-Report.pdf. Published August 2019. Accessed August 7, 2023."},{"issue":"1","key":"10.1016\/j.amepre.2023.11.011_bib0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","article-title":"Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review","volume":"20","author":"Louie","year":"2019","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.amepre.2023.11.011_bib0009","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Removal of data waiver (X-waiver) requirement. SAMHSA. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement. Published 2023. Accessed February 6, 2023."},{"issue":"9","key":"10.1016\/j.amepre.2023.11.011_bib0010","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.amepre.2023.11.011_bib0011","unstructured":"Office of Inspector General, U.S. Department of Health and Human Services. https:\/\/oig.hhs.gov\/oei\/reports\/oei-12-17-00240.pdf. Published January 2020. Accessed February 6, 2023."},{"issue":"3","key":"10.1016\/j.amepre.2023.11.011_bib0012","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMp2012910","article-title":"Racial Health Disparities and Covid-19 \u2014 caution and context","volume":"383","author":"Chowkwanyun","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2023.11.011_bib0013","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1017\/cts.2021.23","article-title":"Health Disparities and equity in the era of COVID-19","volume":"5","author":"Nana-Sinkam","year":"2021","journal-title":"J Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.amepre.2023.11.011_bib0014","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.amepre.2023.11.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.52381","article-title":"Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic","volume":"6","author":"Hailu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2023.11.011_bib0016","unstructured":"Drug Enforcement Administration. Diversion Control Division. COVID-19 FAQ. https:\/\/www.deadiversion.usdoj.gov\/faq\/coronavirus_faq.htm. Published 2020. Accessed November 30, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0017","unstructured":"Drug Enforcement Administration (DEA). DEA, SAMHSA extend COVID-19 telemedicine flexibilities for the prescribing controlled medications for six months while considering comments from the public. United States Drug Enforcement Administration.https:\/\/www.dea.gov\/press-releases\/2023\/05\/09\/dea-samhsa-extend-covid-19-telemedicine-flexibilities-prescribing#:text=\"We%20strongly%20support%20policies%20that,rule%20may%20be%20found%20here. Published May 09, 2023. Accessed August 9, 2023."},{"issue":"1","key":"10.1016\/j.amepre.2023.11.011_bib0018","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jrh.12669","article-title":"Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky","volume":"39","author":"Lei","year":"2023","journal-title":"J Rural Health"},{"issue":"12","key":"10.1016\/j.amepre.2023.11.011_bib0019","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1007\/s11606-021-07083-y","article-title":"Buprenorphine dispensing in Pennsylvania during the COVID-19 pandemic, January to October 2020","volume":"36","author":"Chalasani","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"23","key":"10.1016\/j.amepre.2023.11.011_bib0020","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2020.22154","article-title":"Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic","volume":"324","author":"Cance","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2023.11.011_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108923","article-title":"National trends in buprenorphine prescribing before and during the COVID-19 pandemic","volume":"144","author":"Ali","year":"2023","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.amepre.2023.11.011_bib0022","unstructured":"Chronic conditions data warehouse. Other chronic health, mental health, and potentially disabling conditions. Chronic conditions data warehouse. https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories-other. Published 2023. Accessed February 17, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0023","unstructured":"Federation of State Medical Boards. U.S. States and territories modifying requirements for telehealth in response to COVID-19. Federation of State Medical Boards COVID-19 advocacy. https:\/\/www.fsmb.org\/siteassets\/advocacy\/pdf\/states-waiving-licensure-requirements-for-telehealth-in-response-to-covid-19.pdf. Published May 24, 2023. Accessed March 2, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0024","unstructured":"Ballotpedia. States that issued lockdown and stay-at-home orders in response to the coronavirus (COVID-19) pandemic. Ballotpedia. https:\/\/ballotpedia.org\/States_that_issued_lockdown_and_stay-at-home_orders_in_response_to_the_coronavirus_(COVID-19)_pandemic,_2020. Updated January 5, 2021. Accessed February 17, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0025","unstructured":"Substance Abuse and Mental Health Services Administration. Buprenorphine practitioner locator. SAMHSA. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/find-treatment\/treatment-practitioner-locator. Published 2023. Accessed February 17, 2023."},{"issue":"3","key":"10.1016\/j.amepre.2023.11.011_bib0026","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.amepre.2023.11.011_bib0027","unstructured":"Statistical Methodology and Applications Branch , Data Modeling Branch, Surveillance Research Program, Joinpoint Regression Program [software program]. version 4.9.1.0 , National Cancer Institute , 2022 https:\/\/surveillance.cancer.gov\/joinpoint\/, Accessed January 9, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0028","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report. Published January 4, 2023. Accessed August 7, 2023."},{"issue":"2","key":"10.1016\/j.amepre.2023.11.011_bib0029","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2105\/AJPH.2021.306577","article-title":"Self-reported treatment need and barriers to care for adults with opioid use disorder: the U.S. National Survey on Drug Use and Health, 2015 to 2019","volume":"112","author":"Saini","year":"2022","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.amepre.2023.11.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1574","article-title":"State- and county-level geographic variation in opioid use disorder, medication treatment, and opioid-related overdose among Medicaid enrollees","volume":"4","author":"Lindner","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4","key":"10.1016\/j.amepre.2023.11.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7028","article-title":"Assessment of community-level vulnerability and access to medications for opioid use disorder","volume":"5","author":"Joudrey","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.amepre.2023.11.011_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.2052","article-title":"Quality of opioid use disorder treatment for persons with and without disabling conditions","volume":"6","author":"Thomas","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.amepre.2023.11.011_bib0033","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2023.11.011_bib0034","unstructured":"American College of Emergency Physicians. X-waiver no longer required to treat opioid use disorder. ACEP.https:\/\/www.acep.org\/news\/acep-newsroom-articles\/x-waiver-no-longer-required-to-treat-opioid-use-disorder\/. Published January 13, 2023. Accessed February 26, 2023."},{"issue":"23","key":"10.1016\/j.amepre.2023.11.011_bib0035","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1001\/jama.2020.21512","article-title":"Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic","volume":"324","author":"Huskamp","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amepre.2023.11.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6147","article-title":"Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amepre.2023.11.011_bib0037","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12954-021-00572-7","article-title":"Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives","volume":"18","author":"Aronowitz","year":"2021","journal-title":"Harm Reduct J"},{"issue":"3","key":"10.1016\/j.amepre.2023.11.011_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PHH.0000000000001036","article-title":"How are telehealth laws intersecting with laws addressing the opioid overdose epidemic?","volume":"26","author":"Pepin","year":"2020","journal-title":"J Public Health Manag Pract"},{"key":"10.1016\/j.amepre.2023.11.011_bib0039","unstructured":"Wishner J, Clemans-Cope L, Marks J, Epstein M. Implementing an integrated medication-assisted treatment program at community health centers: lessons from a pilot project in California. Urban Institute. https:\/\/www.urban.org\/sites\/default\/files\/publication\/99009\/2018.09.13_ca_camden_complex_care_mat_eval_final_1.pdf. Published September 2018. Accessed August 7, 2023."},{"key":"10.1016\/j.amepre.2023.11.011_bib0040","unstructured":"Corallo B, Tolbert J, Sharac J, Markus A, Rosenbaum S. Community health centers and medication-assisted treatment for opioid use disorder: issue brief. Kaiser Family Foundation.https:\/\/www.kff.org\/report-section\/community-health-centers-and-medication-assisted-treatment-for-opioid-use-disorder-issue-brief\/. Published August 14, 2020. Accessed August 7, 2023."},{"issue":"11","key":"10.1016\/j.amepre.2023.11.011_bib0041","article-title":"Coverage and prior authorization policies for medications for opioid use disorder in Medicaid managed care [published correction appears in JAMA Health Forum. 2022;3(11):e224653]","volume":"3","author":"Abraham","year":"2022","journal-title":"JAMA Health Forum"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379723004695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379723004695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:12:15Z","timestamp":1760083935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379723004695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0749379723004695"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2023.11.011","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019\u20132022","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2023.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}